A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

SyBridge Technologies Completes Acquisition Of Active Industrial Solutions, Inc. And Active Industrial Solutions Tennessee

February 19, 2021

SyBridge Technologies notes this transaction marks the further expansion by SyBridge in the mobility tooling industry, especially in the fast-growing lighting, fascia, and grille segment.

New York-based private equity firm Crestview Partners established SyBridge in 2019 and committed $200 million of equity to create a market leader spanning across end-markets, geographies, and advanced technological capabilities to provide value-added solutions to its customers.

The combination of AIS and Concours will create the largest tooling and mold solutions provider in North America. In additional to greater economy of scale, this acquisition will also expand Concours’ capabilities in highly complex precision tooling solutions for lighting applications.

Headquartered in Windsor, Ontario, AIS is a leader in engineering, manufacturing and servicing complex plastic injection molds and lighting reflex components for the mobility industry. Founded in 1977, AIS has grown from a mold maker to a tooling solutions provider through continuously investing in the latest technologies and a strong commitment to lean manufacturing.

“AIS has been a strong player with an excellent reputation in quality and operations. Taking the best from both companies, we will create a transformative company to better meet customer needs in today’s global tooling industry,” said Andy Aiton, President of Concours. “The combined company will have a strong footprint across Canada, U.S., Mexico and Asia. This is a major step in our effort to build unmatched ability to take on large global tooling programs in the future.”

Tony Nardone, CEO of SyBridge, added, “This transaction also includes a dedicated service facility in Southern U.S., which gives us a total of four customer service centers in North America. As we look to the future, service and technology are key drivers of our growth strategy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy